All Stories

  1. Structural constraints link differences in neutralization potency of human anti-Eastern equine encephalitis virus monoclonal antibodies
  2. Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region
  3. Potent neutralization of Rift Valley fever virus by human monoclonal antibodies through fusion inhibition
  4. Antibody affinity versus dengue morphology influences neutralization
  5. Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis
  6. Human monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease
  7. Peptide arrays incubated with three collections of human sera from patients infected with mosquito-borne viruses
  8. Peptide arrays of three collections of human sera from patients infected with mosquito-borne viruses
  9. Multi-state design of flexible proteins predicts sequences optimal for conformational change
  10. Broad dengue neutralization in mosquitoes expressing an engineered antibody
  11. Human-likeness of antibody biologics determined by back-translation and comparison with large antibody variable gene repertoires
  12. Immune repertoire fingerprinting by principal component analysis reveals shared features in subject groups with common exposures
  13. Influenza H7N9 Virus Neuraminidase-Specific Human Monoclonal Antibodies Inhibit Viral Egress and Protect from Lethal Influenza Infection in Mice
  14. Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies
  15. Mechanism of differential Zika and dengue virus neutralization by a public antibody lineage targeting the DIII lateral ridge
  16. Peptide arrays of three collections of human sera from patients infected with mosquito-borne viruses
  17. Human VH1-69 Gene-Encoded Human Monoclonal Antibodies against Staphylococcus aureus IsdB Use at Least Three Distinct Modes of Binding To Inhibit Bacterial Growth and Pathogenesis
  18. Harmonization of Zika neutralization assays by using the WHO International Standard for anti-Zika virus antibody
  19. Mucosal Immunization with a pH-Responsive Nanoparticle Vaccine Induces Protective CD8+ Lung-Resident Memory T Cells
  20. Ehrlichia chaffeensis Outer Membrane Protein 1-Specific Human Antibody-Mediated Immunity Is Defined by Intracellular TRIM21-Dependent Innate Immune Activation and Extracellular Neutralization
  21. Multi-State Design of Flexible Proteins Predicts Sequences Optimal for Conformational Change
  22. Plasma deconvolution identifies broadly neutralizing antibodies associated with hepatitis C virus clearance
  23. Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes
  24. New-Onset Post-Transplant Diabetes Mellitus after Allogeneic Hematopoietic Cell Transplant Is Initiated by Insulin Resistance, Not Immunosuppressive Medications
  25. A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection
  26. Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2
  27. A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface
  28. Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk
  29. Antibody Determinants of Influenza Immunity
  30. Structural Diversity of Ultralong CDRH3s in Seven Bovine Antibody Heavy Chains
  31. High frequency of shared clonotypes in human B cell receptor repertoires
  32. Early Human B Cell Response to Ebola Virus in Four U.S. Survivors of Infection
  33. Potent anti-influenza H7 human monoclonal antibody induces separation of hemagglutinin receptor-binding head domains
  34. Dengue and Zika Virus Cross-Reactive Human Monoclonal Antibodies Protect against Spondweni Virus Infection and Pathogenesis in Mice
  35. Mechanism of Enhanced Immature Dengue Virus Attachment to Endosomal Membrane Induced by prM Antibody
  36. Multistate design of influenza antibodies improves affinity and breadth against seasonal viruses
  37. Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope
  38. Influenza Virus–Specific Human Antibody Repertoire Studies
  39. Regulating patterns of binding by changes in the heavy/light chain interface of HIV antibodies
  40. Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth
  41. Antibody-Mediated Protective Mechanisms Induced by a Trivalent Parainfluenza Virus-Vectored Ebolavirus Vaccine
  42. Current Understanding of Humoral Immunity to Enterovirus D68
  43. Human Monoclonal Antibodies That Neutralize Pandemic GII.4 Noroviruses
  44. Human mAbs to Staphylococcus aureus IsdA Provide Protection Through Both Heme-Blocking and Fc-Mediated Mechanisms
  45. Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein
  46. A protective human monoclonal antibody targeting the West Nile virus E protein preferentially recognizes mature virions
  47. Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection
  48. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design
  49. In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model
  50. Potent Neutralizing Human Monoclonal Antibodies Preferentially Target Mature Dengue Virus Particles: Implication for Novel Strategy for Dengue Vaccine
  51. Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap
  52. Pan-Filovirus Serum Neutralizing Antibodies in a Subset of Congolese Ebolavirus Infection Survivors
  53. Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors
  54. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors
  55. A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus
  56. Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection
  57. A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA
  58. Efficacy of Human Monoclonal Antibody Monotherapy Against Bundibugyo Virus Infection in Nonhuman Primates
  59. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein
  60. Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection
  61. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region
  62. Mxra8 is a receptor for multiple arthritogenic alphaviruses
  63. Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus
  64. Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins
  65. Integrating linear optimization with structural modeling to increase HIV neutralization breadth
  66. OUP accepted manuscript
  67. The Marburgvirus-Neutralizing Human Monoclonal Antibody MR191 Targets a Conserved Site to Block Virus Receptor Binding
  68. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms
  69. Role of Non-local Interactions between CDR Loops in Binding Affinity of MR78 Antibody to Marburg Virus Glycoprotein
  70. Structure–function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8
  71. Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans
  72. Epitope and Paratope Mapping Reveals Temperature-Dependent Alterations in the Dengue-Antibody Interface
  73. Immune correlates of protection for dengue: State of the art and research agenda
  74. Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design
  75. Is It Possible to Develop a “Universal” Influenza Virus Vaccine?
  76. Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques
  77. Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance
  78. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody
  79. Treating Flu with Skin of Frog
  80. A human antibody against Zika virus crosslinks the E protein to prevent infection
  81. Monoclonal Antibodies Against the Staphylococcus aureus Bicomponent Leukotoxin AB Isolated Following Invasive Human Infection Reveal Diverse Binding and Modes of Action
  82. Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis
  83. A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein
  84. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus
  85. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination
  86. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice
  87. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein
  88. Cross-Neutralizing and Protective Human Antibody Specificities to Poxvirus Infections
  89. Structural basis for norovirus neutralization by an HBGA blocking human IgA antibody
  90. A “Trojan horse” bispecific-antibody strategy for broad protection against ebolaviruses
  91. Teaching a Clone to Walk, One Step at a Time
  92. Phenome-Wide Association Study to Explore Relationships between Immune System Related Genetic Loci and Complex Traits and Diseases
  93. Structures of Ebola virus GP and sGP in complex with therapeutic antibodies
  94. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence
  95. Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein
  96. Determinants of VH1-46 Cross-Reactivity to Pemphigus Vulgaris Autoantigen Desmoglein 3 and Rotavirus Antigen VP6
  97. Recognition of influenza H3N2 variant virus by human neutralizing antibodies
  98. Frequent Use of the IgA Isotype in Human B Cells Encoding Potent Norovirus-Specific Monoclonal Antibodies That Block HBGA Binding
  99. Characterization of dengue virus 2 growth in megakaryocyte–erythrocyte progenitor cells
  100. Deep sequencing and human antibody repertoire analysis
  101. A Chimeric Pneumovirus Fusion Protein Carrying Neutralizing Epitopes of Both MPV and RSV
  102. Engineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1
  103. Improving Loop Modeling of the Antibody Complementarity-Determining Region 3 Using Knowledge-Based Restraints
  104. Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization
  105. Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1
  106. H7N9 influenza virus neutralizing antibodies that possess few somatic mutations
  107. Host-Primed Ebola Virus GP Exposes a Hydrophobic NPC1 Receptor-Binding Pocket, Revealing a Target for Broadly Neutralizing Antibodies
  108. Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations
  109. Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates
  110. Chimeric Filoviruses for Identification and Characterization of Monoclonal Antibodies
  111. Early Th1 immunity promotes immune tolerance and may impair graft-versus-leukemia effect after allogeneic hematopoietic cell transplantation
  112. Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection
  113. Development of Human Monoclonal Antibodies Against Respiratory Syncytial Virus Using a High Efficiency Human Hybridoma Technique
  114. Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress
  115. Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site
  116. Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity
  117. A New Quaternary Structure Epitope on Dengue Virus Serotype 2 Is the Target of Durable Type-Specific Neutralizing Antibodies
  118. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus
  119. Deciphering the human immunome
  120. Source and Purity of Dengue-Viral Preparations Impact Requirement for Enhancing Antibody to Induce Elevated IL-1β Secretion: A Primary Human Monocyte Model
  121. Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein
  122. Vaccine-elicited antibody that neutralizes H5N1 influenza and variants binds the receptor site and polymorphic sites
  123. Design of Protein Multi-specificity Using an Independent Sequence Search Reduces the Barrier to Low Energy Sequences
  124. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers
  125. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus
  126. Spleen Tyrosine Kinase (Syk) Mediates IL-1β Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection
  127. Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth
  128. Retraction for Messer et al., Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity
  129. Challenges and Opportunities in Developing Respiratory Syncytial Virus Therapeutics
  130. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins
  131. Mechanism of Human Antibody-Mediated Neutralization of Marburg Virus
  132. Structural Basis for Marburg Virus Neutralization by a Cross-Reactive Human Antibody
  133. Influenza Viruses with Receptor-Binding N1 Neuraminidases Occur Sporadically in Several Lineages and Show No Attenuation in Cell Culture or Mice
  134. Antibodies for Infectious Diseases
  135. Use of Human Hybridoma Technology To Isolate Human Monoclonal Antibodies
  136. Committing the Oldest Sins in the Newest Kind of Ways—Antibodies Targeting the Influenza Virus Type A Hemagglutinin Globular Head
  137. Identification of Residues in the Human Respiratory Syncytial Virus Fusion Protein That Modulate Fusion Activity and Pathogenesis
  138. Dengue Viruses Are Enhanced by Distinct Populations of Serotype Cross-Reactive Antibodies in Human Immune Sera
  139. Isolation of Dengue Virus-Specific Memory B Cells with Live Virus Antigen from Human Subjects following Natural Infection Reveals the Presence of Diverse Novel Functional Groups of Antibody Clones
  140. Intracellular neutralization of a virus using a cell-penetrating molecular transporter
  141. Tissue-Specific Expressed Antibody Variable Gene Repertoires
  142. STAT4 Deficiency Fails To Induce Lung Th2 or Th17 Immunity following Primary or Secondary Respiratory Syncytial Virus (RSV) Challenge but Enhances the Lung RSV-Specific CD8+ T Cell Immune Response to Secondary Challenge
  143. Correction for Messer et al., Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity
  144. Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein
  145. Antibody Engineering and Therapeutics
  146. Proof of principle for epitope-focused vaccine design
  147. Combining Single RNA Sensitive Probes with Subdiffraction-Limited and Live-Cell Imaging Enables the Characterization of Virus Dynamics in Cells
  148. Diagnostic errors in interpretation of pediatric musculoskeletal radiographs at common injury sites
  149. Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity
  150. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface
  151. Paramyxoviruses: Respiratory Syncytial Virus and Human Metapneumovirus
  152. The Potent and Broadly Neutralizing Human Dengue Virus-Specific Monoclonal Antibody 1C19 Reveals a Unique Cross-Reactive Epitope on the bc Loop of Domain II of the Envelope Protein
  153. Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses
  154. Differential Accessibility of a Rotavirus VP6 Epitope in Trimers Comprising Type I, II, or III Channels as Revealed by Binding of a Human Rotavirus VP6-Specific Antibody
  155. Impact of new sequencing technologies on studies of the human B cell repertoire
  156. Intermittent Testicular Torsion in the Pediatric Patient: Sonographic Indicators of a Difficult Diagnosis
  157. Antibody Recognition of the Pandemic H1N1 Influenza Virus Hemagglutinin Receptor Binding Site
  158. Exposure to Family Members: Infections and Recent Live Vaccinations
  159. Human antibodies that neutralize respiratory droplet transmissible H5N1 influenza viruses
  160. Universal Flu Vaccines: Primum non nocere
  161. Gold nanorod vaccine for respiratory syncytial virus
  162. Anti Rotavirus Antibody
  163. Human Rotavirus VP6-Specific Antibodies Mediate Intracellular Neutralization by Binding to a Quaternary Structure in the Transcriptional Pore
  164. Crowdsourcing Immunity
  165. Human Germline Antibody Gene Segments Encode Polyspecific Antibodies
  166. E107 Complexity of human naïve B cell repertoires
  167. Discovering naturally processed antigenic determinants that confer protective T cell immunity
  168. Human Monoclonal Antibodies Derived From Memory B Cells Following Live Attenuated Dengue Virus Vaccination or Natural Infection Exhibit Similar Characteristics
  169. Prophylactic and therapeutic testing of Nicotiana-derived RSV-neutralizing human monoclonal antibodies in the cotton rat model
  170. Reversion of Somatic Mutations of the Respiratory Syncytial Virus-Specific Human Monoclonal Antibody Fab19 Reveal a Direct Relationship between Association Rate and Neutralizing Potency
  171. A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin
  172. Secondary mechanisms of diversification in the human antibody repertoire
  173. Molecular mechanisms driving respiratory syncytial virus assembly
  174. Respiratory Syncytial Virus Regulates Human MicroRNAs by Using Mechanisms Involving Beta Interferon and NF-κB
  175. Influenza Human Monoclonal Antibody 1F1 Interacts with Three Major Antigenic Sites and Residues Mediating Human Receptor Specificity in H1N1 Viruses
  176. A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis
  177. Tissue-specific regulatory T cells: biomarker for acute graft-vs-host disease and survival
  178. Unusual Features of Vaccinia Virus Extracellular Virion Form Neutralization Resistance Revealed in Human Antibody Responses to the Smallpox Vaccine
  179. Erratum: Corrigendum: Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors
  180. A Chemically Programmed Antibody Is a Long-Lasting and Potent Inhibitor of Influenza Neuraminidase
  181. Frequency and genetic characterization of V(DD)J recombinants in the human peripheral blood antibody repertoire
  182. Influenza Virus Resistance to Human Neutralizing Antibodies
  183. Respiratory Syncytial Virus Assembles into Structured Filamentous Virion Particles Independently of Host Cytoskeleton and Related Proteins
  184. Location and length distribution of somatic hypermutation-associated DNA insertions and deletions reveals regions of antibody structural plasticity
  185. High-throughput antibody sequencing reveals genetic evidence of global regulation of the naïve and memory repertoires that extends across individuals
  186. Human Respiratory Syncytial Virus Nucleoprotein and Inclusion Bodies Antagonize the Innate Immune Response Mediated by MDA5 and MAVS
  187. Human Peripheral Blood Antibodies with Long HCDR3s Are Established Primarily at Original Recombination Using a Limited Subset of Germline Genes
  188. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions
  189. Human Monoclonal Antibodies to Pandemic 1957 H2N2 and Pandemic 1968 H3N2 Influenza Viruses
  190. Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site
  191. A Critical Phenylalanine Residue in the Respiratory Syncytial Virus Fusion Protein Cytoplasmic Tail Mediates Assembly of Internal Viral Proteins into Viral Filaments and Particles
  192. Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity
  193. Independent Structural Domains in Paramyxovirus Polymerase Protein
  194. Viral Pneumonia
  195. Persistence of Circulating Memory B Cell Clones with Potential for Dengue Virus Disease Enhancement for Decades following Infection
  196. Identification of potential human respiratory syncytial virus and metapneumovirus T cell epitopes using computational prediction and MHC binding assays
  197. Machine learning competition in immunology – Prediction of HLA class I binding peptides
  198. Maturation-Induced Cloaking of Neutralization Epitopes on HIV-1 Particles
  199. Epitope-Specific Human Influenza Antibody Repertoires Diversify by B Cell Intraclonal Sequence Divergence and Interclonal Convergence
  200. A Broadly Neutralizing Human Monoclonal Antibody That Recognizes a Conserved, Novel Epitope on the Globular Head of the Influenza H1N1 Virus Hemagglutinin
  201. Tribute to David T. Karzon, MD and Robert M. Chanock, MD
  202. Activation of protein kinase R is required for induction of stress granules by respiratory syncytial virus but dispensable for viral replication
  203. An Insertion Mutation That Distorts Antibody Binding Site Architecture Enhances Function of a Human Antibody
  204. Research Highlights
  205. Human Metapneumovirus
  206. Respiratory Syncytial Virus
  207. Prevention of Fetal and Early Life Infections Through Maternal–Neonatal Immunization
  208. Respiratory Syncytial Virus and Human Metapneumovirus
  209. Reply to Schlapbach et al
  210. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes
  211. Specificity for Human Hemoglobin Enhances Staphylococcus aureus Infection
  212. Faculty of 1000 evaluation for A size threshold limits prion transmission and establishes phenotypic diversity.
  213. Transforming Growth Factor Beta Is a Major Regulator of Human Neonatal Immune Responses following Respiratory Syncytial Virus Infection
  214. Respiratory Syncytial Virus Induces Host RNA Stress Granules To Facilitate Viral Replication
  215. Surfing a genetic association interaction network to identify modulators of antibody response to smallpox vaccine
  216. Pseudovirion Particles Bearing Native HIV Envelope Trimers Facilitate a Novel Method for Generating Human Neutralizing Monoclonal Antibodies Against HIV
  217. Population‐Based Incidence of Human Metapneumovirus Infection among Hospitalized Children
  218. Regulatory T cell expression of CLA or α4β7 and skin or gut acute GVHD outcomes
  219. Emerging studies of human HIV-specific antibody repertoires
  220. Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus
  221. Naturally Occurring Human Monoclonal Antibodies Neutralize both 1918 and 2009 Pandemic Influenza A (H1N1) Viruses
  222. Faculty of 1000 evaluation for Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial.
  223. Faculty of 1000 evaluation for Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus.
  224. Recent advances in the study of human antibody responses to influenza virus using optimized human hybridoma approaches
  225. The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations
  226. Genetic diversity and evolution of human metapneumovirus fusion protein over twenty years
  227. Faculty of 1000 evaluation for Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target.
  228. The Pediatric Burden of Human Coronaviruses Evaluated for Twenty Years
  229. Coronavirus infection and hospitalizations for acute respiratory illness in young children
  230. Single molecule–sensitive probes for imaging RNA in live cells
  231. Amphiregulin-Deficient Mice Develop Spasmolytic Polypeptide Expressing Metaplasia and Intestinal Metaplasia
  232. Capturing the Spectrum of Interaction Effects in Genetic Association Studies by Simulated Evaporative Cooling Network Analysis
  233. Faculty of 1000 evaluation for Antibody recognition of a highly conserved influenza virus epitope.
  234. Faculty of 1000 evaluation for Antigen-specific human polyclonal antibodies from hyperimmunized cattle.
  235. Faculty of 1000 evaluation for Estrogen directly activates AID transcription and function.
  236. A Chimeric A2 Strain of Respiratory Syncytial Virus (RSV) with the Fusion Protein of RSV Strain Line 19 Exhibits Enhanced Viral Load, Mucus, and Airway Dysfunction
  237. Faculty of 1000 evaluation for Engineering microRNA responsiveness to decrease virus pathogenicity.
  238. Human metapneumovirus nucleoprotein and phosphoprotein interact and provide the minimal requirements for inclusion body formation
  239. Integrated analysis of genetic and proteomic data identifies biomarkers associated with adverse events following smallpox vaccination
  240. An Alphavirus Replicon-Based Human Metapneumovirus Vaccine Is Immunogenic and Protective in Mice and Cotton Rats
  241. Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope
  242. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors
  243. Respiratory syncytial virus uses a Vps4-independent budding mechanism controlled by Rab11-FIP2
  244. Genetic Basis for Adverse Events after Smallpox Vaccination
  245. An optimized electrofusion-based protocol for generating virus-specific human monoclonal antibodies
  246. Functional Maturation of the Human Antibody Response to Rotavirus
  247. Immunodominance of the VH1-46 Antibody Gene Segment in the Primary Repertoire of Human Rotavirus-Specific B Cells Is Reduced in the Memory Compartment through Somatic Mutation of Nondominant Clones
  248. A Clinical Isolate Strain of Respiratory Syncytial Virus (RSV) Causes Airway Obstruction and Histopathology in Mice Similar to Severe RSV Disease in Infants
  249. Human Metapneumovirus
  250. Respiratory Syncytial Virus
  251. Faculty of 1000 evaluation for Duration of humoral immunity to common viral and vaccine antigens.
  252. Faculty of 1000 evaluation for Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing.
  253. Faculty of 1000 evaluation for A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis.
  254. Venezuelan Equine Encephalitis Virus Replicon Particles Encoding Respiratory Syncytial Virus Surface Glycoproteins Induce Protective Mucosal Responses in Mice and Cotton Rats
  255. Genetic Predisposition for Adverse Events after Vaccination
  256. Evaporative cooling feature selection for genotypic data involving interactions
  257. A Recombinant Human Monoclonal Antibody to Human Metapneumovirus Fusion Protein That Neutralizes Virus In Vitro and Is Effective Therapeutically In Vivo
  258. Evidence for preferential Ig gene usage and differential TdT and exonuclease activities in human naïve and memory B cells
  259. Faculty of 1000 evaluation for Ab and T cell epitopes of influenza A virus, knowledge and opportunities.
  260. Using the natural evolution of a rotavirus-specific human monoclonal antibody to predict the complex topography of a viral antigenic site
  261. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools
  262. Tissue-Specific Regulation of CD8+ T-Lymphocyte Immunodominance in Respiratory Syncytial Virus Infection
  263. Faculty of 1000 evaluation for The histopathology of fatal untreated human respiratory syncytial virus infection.
  264. Faculty of 1000 evaluation for Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.
  265. Nanoscale tools for rapid and sensitive diagnosis of viruses
  266. Faculty of 1000 evaluation for Low-coverage vaccination strategies for the conservation of endangered species.
  267. Human Metapneumovirus Fusion Protein Vaccines That Are Immunogenic and Protective in Cotton Rats
  268. Examination of a Fusogenic Hexameric Core from Human Metapneumovirus and Identification of a Potent Synthetic Peptide Inhibitor from the Heptad Repeat 1 Region
  269. Introduction
  270. Low expression of the interleukin (IL)-4 receptor alpha chain and reduced signalling via the IL-4 receptor complex in human neonatal B cells
  271. Feature Selection using a Random Forests Classifier for the Integrated Analysis of Multiple Data Types
  272. Cellular Immune Responses to Diluted and Undiluted Aventis Pasteur Smallpox Vaccine
  273. Cytokine Expression Patterns Associated with Systemic Adverse Events following Smallpox Immunization
  274. Faculty of 1000 evaluation for A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines.
  275. Faculty of 1000 evaluation for Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
  276. :Vaccines: Frontiers in Design and Development
  277. Automated image analysis of atomic force microscopy images of rotavirus particles
  278. Hybrid grammar-based approach to nonlinear dynamical system identification from biological time series
  279. Detection of viral infections using colloidal quantum dots
  280. The Role of Human Metapneumovirus in Upper Respiratory Tract Infections in Children: A 20‐Year Experience
  281. The Transmembrane Domain of the Respiratory Syncytial Virus F Protein Is an Orientation-Independent Apical Plasma Membrane Sorting Sequence
  282. Viral Pneumonia
  283. Rotavirus-Specific CD5+ B Cells in Young Children Exhibit a Distinct Antibody Repertoire Compared with CD5− B Cells
  284. Reply
  285. Transcriptional Control of Activation-Induced Cytidine Deaminase and Error-Prone DNA Polymerases Is Functionally Mature in the B Cells of Infants at Birth
  286. Faculty of 1000 evaluation for Altered TCR signaling from geometrically repatterned immunological synapses.
  287. Human Metapneumovirus Infection Plays an Etiologic Role in Acute Asthma Exacerbations Requiring Hospitalization in Adults
  288. The Transmembrane Domain of the Respiratory Syncytial Virus F Protein Is an Orientation-Independent Apical Plasma Membrane Sorting Sequence
  289. Prospective Study of the Incidence, Clinical Features, and Outcome of Symptomatic Upper and Lower Respiratory Tract Infections by Respiratory Viruses in Adult Recipients of Hematopoietic Stem Cell Transplants for Hematologic Malignancies
  290. A Prospective Study Comparing Human Metapneumovirus with Other Respiratory Viruses in Adults with Hematologic Malignancies and Respiratory Tract Infections
  291. The Cotton Rat (Sigmodon hispidus) Is a Permissive Small Animal Model of Human Metapneumovirus Infection, Pathogenesis, and Protective Immunity
  292. Identification of an H-2Db-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus
  293. Faculty of 1000 evaluation for Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
  294. Human metapneumovirus infection in children hospitalized for wheezing
  295. Natural Evolution of a Human Virus-Specific Antibody Gene Repertoire by Somatic Hypermutation Requires Both Hotspot-Directed and Randomly-Directed Processes
  296. Faculty of 1000 evaluation for Stable antibody expression at therapeutic levels using the 2A peptide.
  297. Faculty of 1000 evaluation for Serum IgG mediates mucosal immunity against rotavirus infection.
  298. Pseudovirion Particle Production by Live Poxvirus Human Immunodeficiency Virus Vaccine Vector Enhances Humoral and Cellular Immune Responses
  299. Prevalence of Reovirus‐Specific Antibodies in Young Children in Nashville, Tennessee
  300. Application of semiconductor fluorescent nanocrystals as optical probes for rapid early viral detection
  301. Progression of Respiratory Syncytial Virus Infection Monitored by Fluorescent Quantum Dot Probes
  302. Differential Regulation of Granzyme and Perforin in Effector and Memory T Cells following Smallpox Immunization
  303. VH1-46 Is the Dominant Immunoglobulin Heavy Chain Gene Segment in Rotavirus-Specific Memory B Cells Expressing the Intestinal Homing Receptor  4 7
  304. Smallpox Vaccination Does Not Elevate Systemic Levels of Prothrombotic Proteins Associated with Ischemic Cardiac Events
  305. Faculty of 1000 evaluation for Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease?
  306. Cooperativity of actin and microtubule elements during replication of respiratory syncytial virus
  307. Introduction
  308. Human Metapneumovirus as a Major Cause of Human Respiratory Tract Disease
  309. Vaccination Success Rate and Reaction Profile With Diluted and Undiluted Smallpox Vaccine
  310. Faculty of 1000 evaluation for A role for Streptococcus pneumoniae in virus-associated pneumonia.
  311. Faculty of 1000 evaluation for An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus.
  312. Human Metapneumovirus and Lower Respiratory Tract Disease in Children
  313. Adverse Events after Smallpox Immunizations Are Associated with Alterations in Systemic Cytokine Levels
  314. Effect of Zinc Salts on Respiratory Syncytial Virus Replication
  315. Faculty of 1000 evaluation for Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120.
  316. Human Metapneumovirus and Lower Respiratory Tract Disease in Otherwise Healthy Infants and Children
  317. B-Cell Development
  318. Apical recycling systems regulate directional budding of respiratory syncytial virus from polarized epithelial cells
  319. Fatal Hemophagocytic Lymphohistiocytosis Associated with Epstein-Barr Virus Infection in a Patient with a Novel Mutation in the Signaling Lymphocytic Activation Molecule--Associated Protein
  320. Infant and Adult Human B Cell Responses to Rotavirus Share Common Immunodominant Variable Gene Repertoires
  321. Faculty of 1000 evaluation for Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.
  322. Respiratory Syncytial Virus Nucleoprotein-Specific Cytotoxic T-Cell Epitopes in a South African Population of Diverse HLA Types Are Conserved in Circulating Field Strains
  323. Immunology of viral respiratory tract infection in infancy
  324. CD154 Regulates Primate Humoral Immunity to Influenza
  325. Planar growth faults in double-layered or triple-layered (Ca,Sr)-ruthenate single crystals by the self-flux technique
  326. Faculty of 1000 evaluation for Combinatorial immunoglobulin light chain variability creates sufficient B cell diversity to mount protective antibody responses against pathogen infections.
  327. Identification of a novel human leucocyte antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein
  328. Generation of recombinant human monoclonal antibodies to rotavirus from single antigen-specific B cells selected with fluorescent virus-like particles
  329. Faculty of 1000 evaluation for Mortality associated with influenza and respiratory syncytial virus in the United States.
  330. Faculty of 1000 evaluation for Respiratory syncytial virus-induced activation of nuclear factor-kappaB in the lung involves alveolar macrophages and toll-like receptor 4-dependent pathways.
  331. Faculty of 1000 evaluation for A common haplotype of interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children.
  332. Faculty of 1000 evaluation for Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing.
  333. The Human Polymeric Immunoglobulin Receptor Facilitates Invasion of Epithelial Cells by Streptococcus pneumoniae in a Strain-Specific and Cell Type-Specific Manner
  335. Influence of Maternal Antibodies on Neonatal Immunization against Respiratory Viruses
  336. Respiratory syncytial virus vaccine development
  337. Passively Acquired Antibodies Suppress Humoral But Not Cell-Mediated Immunity in Mice Immunized with Live Attenuated Respiratory Syncytial Virus Vaccines
  338. CD40-Ligand in Primate Cardiac Allograft and Viral Immunity
  339. Genetic and Structural Determinants of Virus Neutralizing Antibodies
  340. Recurrent Achromobacter xylosoxidans Bacteremia Associated with Persistent Lymph Node Infection in a Patient with Hyper-Immunoglobulin M Syndrome
  341. Recurrent Pneumococcal Arthritis as the Presenting Manifestation of X-Linked Agammaglobulinemia
  342. Aktuelle Ansätze zur Impfstoffentwicklung gegen Respiratory-Syncytial-Virus (RSV)
  343. Evaluation of a Live, Cold‐Passaged, Temperature‐Sensitive, Respiratory Syncytial Virus Vaccine Candidate in Infancy
  344. A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3
  345. Passive IgA Monoclonal Antibody Is No More Effective Than IgG at Protecting Mice from Mucosal Challenge with Respiratory Syncytial Virus
  346. The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo
  347. Monoclonal Antibody-Resistant Mutants Selected with a Respiratory Syncytial Virus-Neutralizing Human Antibody Fab Fragment (Fab 19) Define a Unique Epitope on the Fusion (F) Glycoprotein
  348. Immune responses of infants to infection with respiratory viruses and live attenuated respiratory virus candidate vaccines
  349. Isolation of a Second Recombinant Human Respiratory Syncytial Virus Monoclonal Antibody Fragment (Fab RSVF2–5) that Exhibits Therapeutic Efficacy In Vivo
  350. Evaluation of a Live, Attenuated Respiratory Syncytial Virus (RSV)Vaccine Candidate, cpts 248/404, in Infancy • 931
  351. Evaluation of Two Live, Cold‐Passaged, Temperature‐Sensitive Respiratory Syncytial Virus Vaccines in Chimpanzees and in Human Adults, Infants, and Children
  352. Nucleotide Sequence Analysis of the Respiratory Syncytial Virus Subgroup A Cold-Passaged (cp) Temperature Sensitive (ts)cpts-248/404 Live Attenuated Virus Vaccine Candidate
  353. The role of antibodies in respiratory viral immunity
  354. Live Subgroup B Respiratory Syncytial Virus Vaccines that Are Attenuated, Genetically Stable, and Immunogenic in Rodents and Nonhuman Primates
  355. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene
  356. Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization
  357. A Cold-Passaged, Attenuated Strain of Human Respiratory Syncytial Virus Contains Mutations in the F and L Genes
  358. Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus
  359. Current approaches to the development of vaccines against disease caused by respiratory syncytial virus (RSV) and parainfluenza virus (PIV) A meeting report of the WHO Programme for Vaccine Development
  360. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines
  361. Recombinant human respiratory syncytial virus (RSV)monoclonal antibody Fab is effective therapeutically when introduced directlyinto the lungs of RSV-infected mice.
  362. A further attenuated derivative of a cold-passaged temperature-sensitive mutant of human respiratory syncytial virus retains immunogenicity and protective efficacy against wild-type challenge in seronegative chimpanzees
  363. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis
  364. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV
  365. Human monoclonal Fab fragments derived from a combinatorial library bind to respiratory syncytial virus F glycoprotein and neutralize infectivity.